Cellcentric Limited

Topivert Pharma Limited

Respivert Limited

Gareth Harbottle

David Michel Adrien Taddei

Stephen Thom

Matthew Colin Thor Fyfe

Jonathan Shannon

Thomas Matthew Baker

Silvia Paoletta

Neil Anthony Pegg

Aaron Rigby

Vedran Hasimbegovic

Stuart Thomas Onions

Premji Meghani

Richard James Brown

Colin Peter Sambrook-Smith

Don Smyth

David Wood

Donald Alan Gilbert

Paul Baguley

Colin Lindley

John Paul Madeley

James Vaughan Morey

Jonathan Trevorrow

Ting Qin

A process for producing a compound of the following formula (I) which process comprises: (a) treating a compound of the following formula (5) with a compound of the following formula (6) to generate an intermediate compound of the following formula (7); (b) treating a compound of formula (7) as defined above with a compound of the following formula (8); and (c) recovering a compound of formula (I) as defined above. The compound of formula (I) is a promising modulator of p300/CBP activity that has potential utility in treating cancers, including prostate cancer, haematological cancers, bladder cancer and lung cancer. 

Process for preparing modulators of p300 and/or CBP

A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer. 

Pharmaceutical compounds

A compound which is a benzimidazole of formula (I): wherein X is a 5-membered heteroaryl group selected from the following: or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer. 

There are provided compounds of formula I, wherein Rto R, Rto R, L and Xto Xhave meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Kinase inhibitors

There are provided compounds of formula I, wherein R, R, Rto R, R, R, X, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Urea derivatives useful as kinase inhibitors

Growing community of inventors

Nottingham, United Kingdom

Gareth Harbottle